Retinal Disease

The use of OCT during a technology-based eye care services examination did not improve diagnostic accuracy for glaucoma or retinal diseases, according to a study.

Repeated intravitreal injections may result in glaucomatous damage, according to research done at New York Eye and Ear Infirmary of Mount Sinai.

Rishi P. Singh, MD, discusses how the Cole Eye Institute at the Cleveland Clinic in Ohio has been adapting to treat ophthalmology patients during the COVID-19 pandemic.

We have come to the third and final installment in our spontaneous series about outer retinal anomalies found on OCT: focal choroidal excavations.

ATLANTA – Maculogix has taken the 45-pound tabletop dark adaptation testing device, AdaptDx, and turned it into a head-mounted technology managed by an onboard artificial intelligence technician called Theia.

TREVISO, Italy — At the Retina 2020: New Trends meeting, Claudio Azzolini, MD, speaks about e-health and the many opportunities it provides for more equal and accessible health care. Several universities in Italy and other European countries are involved in e-health projects.

QR-421a has received rare pediatric disease designation from the FDA for the treatment of retinitis pigmentosa, according to a press release from ProQR Therapeutics.

Adverum Biotechnologies has made significant progress in its lead clinical program for intravitreal gene therapy for retinal diseases, Leone Patterson, CEO and president, said at the J.P. Morgan Healthcare Conference.

With recent acquisitions, Glaukos now has multiple products in development that expand its reach outside of the glaucoma space and into more comprehensive ophthalmology, CEO Tom Burns said at the J.P. Morgan Healthcare Conference.

Santen plans to break into the U.S. glaucoma market in 2020 with the introduction of the DE-128 microshunt, according to a speaker at the 38th annual J.P. Morgan Healthcare Conference.